Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04861064 · ClinicalTrials.gov registry record · Phase 2

Weekly Sirolimus Therapy

A Phase 2 study of Lymphatic Malformation and Venous Malformation, sponsored by Medical University of South Carolina.

Recruiting
Registry status
Phase 2
Development phase
24
Enrollment target
1
Study location

NCT04861064 is a Phase 2 study of Lymphatic Malformation and Venous Malformation that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04861064, a Phase 2 study of Lymphatic Malformation and Venous Malformation, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients when taken once or twice a day for several months. Unfortunately there are many side effects associated with this medication, some of which can be severe including, neutropenia, oral ulcerations, and lab abnormalities. The purpose of this study is to determine if once weekly dosed sirolimus will be effective for the treatment of venous and lymphatic malformations. Additionally, the study will evaluate patient satisfaction and identify adverse effects. Participants will be on the medication for 6 months with an option to continue after this time period.

Interventions

  • DRUG Sirolimus

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-01-18
Est. Completion 2027-12
Phase Phase 2

What the Registry Record Tells You About NCT04861064

The ClinicalTrials.gov registry entry for NCT04861064 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphatic Malformation appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.

NCT04861064 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT04861064 about?

NCT04861064 is a clinical study titled "Weekly Sirolimus Therapy". In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients when taken once or twice a day for several months. Unfortunately there are many side effects associated with this medication, some of which c...

What is the current status of trial NCT04861064?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-01-18. Estimated completion is 2027-12.

What conditions does trial NCT04861064 study?

This clinical trial studies the following conditions: Lymphatic Malformation, Venous Malformation.

What interventions are being tested in trial NCT04861064?

The interventions under investigation include: Sirolimus (DRUG).

Who is sponsoring clinical trial NCT04861064?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04861064 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphatic Malformation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.